"Almotriptan"

Almotriptan An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationThere is minimal published experience with almotriptan during breastfeeding, although the dose in milk appears to be low. If almotriptan is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.Drug

Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake. The study is a randomized, open-label, parallel-group, single-attack study with 12.5 mg almotriptan and 50 mg ubrogepant. 645 patients with migraine with or without aura according to the third edition of the International Classification of Headache Disorders (ICHD-3) will be included.Each subject will randomly be allocated to one treatment, and given 42 days to treat a single qualifying migraine attack of moderate to severe intensity.

to severe pain and 2.4 for mild pain. Intranasal sumatriptan is also effective for pain free at two hours (NNT=3.1).33In studies comparing sumatriptan to other triptans, zolmitriptan and almotriptan showed similar efficacy.33 Rizatriptan 10 mg was superior to all doses of sumatriptan for achieving pain free at two hours. Rizatriptan 5 mg had similar efficacy to sumatriptan 50 mg. Eletriptan 40 mg and 80

to severe pain and 2.4 for mild pain. Intranasal sumatriptan is also effective for pain free at two hours (NNT=3.1).33In studies comparing sumatriptan to other triptans, zolmitriptan and almotriptan showed similar efficacy.33 Rizatriptan 10 mg was superior to all doses of sumatriptan for achieving pain free at two hours. Rizatriptan 5 mg had similar efficacy to sumatriptan 50 mg. Eletriptan 40 mg and 80

- HT1 receptor agonists (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) and nonsteroidal anti-inflammatory drugs (acetylsalicylic acid, diclofenac, ibuprofen) a. Presented is the ACT specified by the G-BA. b. For the implementation of individualized therapy in a study of direct comparison, the investigator is expected to have a selection of several attacks with or without aura Individualized treatmentb taking into account the pretreatment, the severity of the attack and existing concomitant diseases, choosing from selective serotonin 5-HT1 receptor agonists (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) and nonsteroidal anti-inflammatory drugs (acetylsalicylic acid, diclofenac, ibuprofen) Added

* Tools * Search * Home Managing medicines for people with sulfonamide allergy Published 2 October 2024 Topics: Adverse effects · Allergy and immunology · Almotriptan · 7 more Anaphylaxis · Bendroflumethiazide · Co-trimoxazole · Naratriptan · Sulfasalazine · Sumatriptan · Tamsulosin · Less Points to consider when prescribing and supplying medicines to people with sulfonamide allergy. Contents 1 for people with sulfonamide allergy include basalazide and mesalazine. TriptansSumatriptan, almotriptan and naratriptan contain a sulfonamide chemical group so a risk versus benefit analysis should be conducted before prescribing. Eletriptan, frovatriptan, rizatriptan and zolmitriptan do not contain the sulfonamide chemical group so can be used. Alpha-blockersTamsulosin contains a sulfonamide chemical

and adolescents.• CBT appears to be effective for reducing migraine frequency in children and adolescents.• First-line acute migraine treatment in children is ibuprofen; adolescents may benefit from sumatriptan/naproxen tablets, zolmitriptan nasal spray, sumatriptan nasal spray, rizatriptan, or almotriptan.• Overuse of acute medication to treat migraines increases headache frequency.From the AFP EditorsUpdated ) — Almotriptan (Axert) oral dissolving tablets 6.25- and 12.5-mg tablets improve pain at two hours (weak evidence) 6.25- and 12.5-mg tablets do not relieve pain at 2 hours (weak evidence) Eletriptan (Relpax) oral tablets

Triptans You need to be logged in to see the full monograph.LoginUSE OF TRIPTANS IN PREGNANCYDate of issue: April 2020, Version: 2.1‘Triptans’ (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) are 5HT1-receptor agonists used in the treatment of acute migraine and cluster headache. They are not used for migraine prophylaxis. The available data

reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double -blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup

Oral sumatriptan and almotriptan--delimiting the MAOI effect. (1) To investigate whether a parsimonious model for sumatriptan pharmacokinetics can apply to oral administration; (2) for a successful model, whether a monoamine oxidase A inhibitor (MAOI-A) perturbs it; and (3) whether such a model is generalizable to oral almotriptan. These goals respond to statements in US product labeling (both without and with a concomitant MAOI-A) and also for oral almotriptan. A model for oral sumatriptan pharmacokinetics can be found using the differential calculus, and it is generalizable to oral almotriptan. The model suggests that an MAOI-A probably has greater effect on elimination kinetics than first-pass metabolism, and that this interaction appears to be overstated in product labeling.

Method Development and Validation of Almotriptan in Human Plasma by HPLC Tandem Mass Spectrometry: Application to Pharmacokinetic Study A simple, sensitive and selective method has been developed for quantification of Almotriptan (AL) in human plasma using Almotriptan-d(6) (ALD6) as an internal standard. Almotriptan and Almotriptan-d(6) were detected with proton adducts at m/z 336.1→201.1 and 342.2→207.2 in multiple reaction monitoring (MRM) positive mode, respectively. The method was linear over a concentration range of 0.5-150.0 ng/mL. The limit of detection (LOD) and limit of quantification (LOQ) for Almotriptan were 0.2 pg/mL and 0.5 ng/mL, respectively. Liquid-liquid extraction was used followed by MS/MS (ion spray). The method was shown to be precise with an average within-run

Danish residents with access to public healthcare between 1 January 1994 and 31 October 2019 and summarise informative trends of all purchases of triptans in Denmark in the same period. Complete purchase records of Sumatriptan, Naratriptan, Zolmitriptan, Rizatriptan, Almotriptan, Eletriptan, and Frovatriptan were used. Over a 25-year period, triptan use increased from 345 to 945 defined daily doses